Results 11 to 20 of about 1,670,952 (313)

Nontuberculous Mycobacterial Lung Disease in the Patients with Cystic Fibrosis—A Challenging Diagnostic Problem

open access: yesDiagnostics, 2022
Background: Cystic fibrosis (CF) is an autosomal, recessive genetic disorder, caused by a mutation in the cystic fibrosis transmembrane conductance receptor regulator (CFTR) gene.
Dorota Wyrostkiewicz   +6 more
doaj   +1 more source

Factors Predictive for Immunomodulatory Therapy Response and Survival in Patients with Hypersensitivity Pneumonitis—Retrospective Cohort Analysis

open access: yesDiagnostics, 2022
Hypersensitivity pneumonitis (HP) is one of the interstitial lung diseases with clearly established diagnostic criteria. Nevertheless, pharmacologic treatment recommendations are still lacking. Most specialists use steroids as first-line drugs, sometimes
Katarzyna B. Lewandowska   +11 more
doaj   +1 more source

Scleroderma lung disease [PDF]

open access: yesEuropean Respiratory Review, 2013
Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterised by endothelial dysfunction resulting in a small-vessel vasculopathy, fibroblast dysfunction with resultant excessive collagen production and fibrosis, and immunological abnormalities.
Joshua J. Solomon   +5 more
openaire   +3 more sources

Pulmonary amyloidosis mimicking interstitial lung disease and malignancy - A case series with a review of a pulmonary patterns

open access: yesRespiratory Medicine Case Reports, 2021
Background: Amyloidosis is an uncommon condition, which results from accumulation of misfolded extracellular insoluble protein in tissues and organs of the body, causing its damage and dysfunction.
Katarzyna Zimna   +4 more
doaj   +1 more source

Tuberculous Pericarditis—Own Experiences and Recent Recommendations

open access: yesDiagnostics, 2022
Tuberculous pericarditis (TBP) accounts for 1% of all forms of tuberculosis and for 1–2% of extrapulmonary tuberculosis. In endemic regions, TBP accounts for 50–90% of effusive pericarditis; in non-endemic, it only accounts for 4%.
Małgorzata Dybowska   +6 more
doaj   +1 more source

Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy

open access: yesDiagnostics, 2023
The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung transplantation.
Aneta Kacprzak   +2 more
doaj   +1 more source

Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension—A Challenging Mystery

open access: yesDiagnostics, 2023
Sarcoidosis has been a well-recognised risk factor for pulmonary hypertension (PH) for a long time, but still, the knowledge about this concatenation is incomplete.
Aneta Kacprzak   +2 more
doaj   +1 more source

Proceedings: Regenerative Medicine for Lung Diseases: A CIRM Workshop Report. [PDF]

open access: yes, 2017
The mission of the California Institute of Regenerative Medicine (CIRM) is to accelerate treatments to patients with unmet medical needs. In September 2016, CIRM sponsored a workshop held at the University of California, Los Angeles, to discuss ...
DeWitt, Natalie D   +2 more
core   +1 more source

Serum Levels of Interleukin-8 and Tumor Necrosis Factor-alpha in Coal Workers' Pneumoconiosis: One-year Follow-up Study

open access: yesSafety and Health at Work, 2010
Objectives: Various cytokines induced by inhalation of coal dust may mediate inflammation and lead to tissue damage or fibrosis, such as coal workers' pneumoconiosis (CWP).
Jong Seong Lee   +5 more
doaj   +1 more source

Guanylyl cyclase activation reverses resistive breathing–induced lung injury and inflammation [PDF]

open access: yes, 2015
Inspiratory resistive breathing (RB), encountered in obstructive lung diseases, induces lung injury. The soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway is down-regulated in chronic and acute animal models of RB, such as ...
Brouckaert, Peter   +15 more
core   +2 more sources

Home - About - Disclaimer - Privacy